论文部分内容阅读
目的探讨持续皮下输注胰岛素(CSⅡ)联合动态血糖监测系统(CGMS)治疗T2DM的疗效。方法 78例T2DM患者随机分为3组,CSⅡ+CGMS组、CSⅡ组和MSⅡ组,各26例,比较治疗3 d的日内平均血糖(MBG)、平均血糖漂移幅度(MAGE)、血糖达标所需时间、胰岛素用量、低血糖情况。结果 3组治疗3d后的MBG以CSⅡ+CGMS组、CSⅡ组较MSⅡ组下降更明显(P<0.01)。CSⅡ+CGMS组的MAGE显著低于CSⅡ组和MSⅡ组(P<0.01)。血糖达标所需时间MSⅡ组>CSⅡ组CSⅡ+CGMS组(P<0.01),所需胰岛素用量MSⅡ组>CSⅡ+CGMS组(P<0.01),MSⅡ组>CSⅡ组(P<0.05),CSⅡ+CGMS组在动态血糖监测时间段低血糖事件发生44次,无症状性低血糖39次,CSⅡ组低血糖事件发生10次,MSⅡ组低血糖事件发生14次。结论 CSⅡ+CGMS治疗2型糖尿病更加安全有效。
Objective To investigate the efficacy of continuous subcutaneous infusion of insulin (CS Ⅱ) combined with dynamic glucose monitoring system (CGMS) in the treatment of T2DM. Methods Totally 78 T2DM patients were randomly divided into three groups: CSⅡ + CGMS group, CSⅡgroup and MSⅡ group, with 26 cases in each group. The intra-day mean blood glucose (MBG), mean blood glucose drift (MAGE) Time, insulin dosage, hypoglycemia. Results After 3 days of treatment, MBG decreased more significantly in CS Ⅱ + CGMS group and CS Ⅱ group than in MS Ⅱ group (P <0.01). MAGE in CSⅡ + CGMS group was significantly lower than that in CSⅡ and MSⅡgroups (P <0.01). (P <0.01), MSⅡ> CSⅡ + CGMS (P <0.01), MSⅡ> CSⅡ (P <0.05), CSⅡ + CGMS group had 44 hypoglycemic events during the period of dynamic glucose monitoring, asymptomatic hypoglycemia 39 times, hypoglycemic episode 10 times in CSⅡ group and hypoglycemia event 14 times in MSⅡ group. Conclusion CS Ⅱ + CGMS is more safe and effective in treating type 2 diabetes mellitus.